BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces the enrollment of the first patient in the Phase 1B clinical trial of Aduro’s CRS-207 therapeutic cancer vaccine combined with chemotherapy in patients newly diagnosed with malignant pleural mesothelioma (ClinicalTrials.gov Identifier NCT01675765). Patients will receive two prime vaccinations with CRS-207, followed by standard-of-care chemotherapy (pemetrexed and cisplatin) and at least 2 boost vaccinations after chemotherapy. The trial is being conducted at two sites: the National Cancer Institute (NCI) in Bethesda, Maryland (under a Cooperative Research and Development Agreement) and the H. Lee Moffitt Cancer Center in Tampa, Florida.
